The variables that were identified as significant in the univariate analysis, such as age (as a categorical variable), modus operandi, histological subtype, tumor grade, ascites, postoperative distant metastasis, and
adjuvant therapy, were entered into a Cox model to define the independent factors that predict the postoperative survival time.
The long inclusion period of this cohort inadvertently causes differences in adjuvant treatment between patients diagnosed in 2002 versus 2008, the most important of which is the addition of oxaliplatin to
adjuvant therapy in 2004.
Median age (range), yr 61 (30-79) Sex Male 23 Female 13 Primary Site Left lung 20 Right lung 16 Histologic properties Squamos cell 23 Adenocarcinoma 5 Non-small cell (undifferentiated) 7 Mixed (adenosquamous) 1 Stage IIIA 31 IIIB 5 Neoadjuvant therapy 18 Chemotherapy 2 Radiation 0 Chemoradiation 12
Adjuvant therapy 8 Chemotherapy 1 Radiation 1 Chemoradiation 6 Surgery Alone 10 Table 2: Postoperative complications in patients with stage III NSCLC.
However, there are several limitations in undertaking
adjuvant therapy.
Postenucleation
adjuvant therapy in high risk retinoblastoma.
Yet, in many cases, surgeons were unaware whether their patient was resistant to taking
adjuvant therapy (56 percent of patients), understood the risks and benefits of adjuvant treatment (54 percent), or could not tolerate adjuvant treatment (52 percent).
The choice of the type of
adjuvant therapy depends on many factors, such as whether the cancer cells contain hormone receptors (estrogen and progesterone), Her2 neu expression, the grade of tumor and the size of tumor and lymph nodes.
Adjuvant therapy is given to women with early-stage (localized) breast cancer who have had initial treatment -- surgery with or without radiation therapy -- with the goal of reducing the risk of cancer recurrence and/or the occurrence of metastatic disease.
Fall in mortality from breast cancer is due almost equally to screening and
adjuvant therapy [News Roundup].
Adjuvant therapy was standardized, and the only variation was in the instrument used to remove the tonsils.
Accordingly, the three parties have launched a clinical study of immune cell therapy for postoperative
adjuvant therapy in pancreatic cancer.
*
Adjuvant therapy. Chemotherapy and/or radiation given after surgery to prevent cancer recurrence.